{"transactions":[{"id":2052832,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-19T01:00:34.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":15001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":15001,"source":{"system":"sec-edgar","filing":"0000899243-23-002099","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323002099/doc4.xml","form_type":"4"}},{"id":2075665,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares issued pursuant to the exercise of the options reported herein represent 30,000 shares underlying an overall option award of 60,000 shares. All exercised options had vested. As to the overall option for 60,000 shares, 25% of the shares underlying the option vested on April 1, 2021 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":30000,"derivative":{"exercise_price":60.26,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075664,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":100,"price":284.65,"value":28465.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075663,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":400,"price":283.43,"value":113372.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.11 to $283.83, inclusive."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075662,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":400,"price":282.13,"value":112852.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.20, inclusive."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075661,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":1000,"price":280.92,"value":280920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.61 to $281.44, inclusive."}],"balance_after":900,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075660,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":2620,"price":279.96,"value":733495.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.56 to $280.42, inclusive."}],"balance_after":1900,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075659,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":3003,"price":279.15,"value":838287.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $278.53 to $279.50, inclusive."}],"balance_after":4520,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075658,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":700,"price":277.83,"value":194481.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.49 to $278.13, inclusive."}],"balance_after":7523,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075657,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":700,"price":276.67,"value":193669.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.40 to $277.31, inclusive."}],"balance_after":8223,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075656,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":811,"price":275.7,"value":223592.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.24 to $276.23, inclusive."}],"balance_after":8923,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075655,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":3019,"price":274.56,"value":828896.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.19 to $275.13, inclusive."}],"balance_after":9734,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075654,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":2471,"price":273.54,"value":675917.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.04 to $274.01, inclusive."}],"balance_after":12753,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075653,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":5534,"price":272.68,"value":1509011.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.04 to $273.02, inclusive."}],"balance_after":15224,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075652,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":2084,"price":271.54,"value":565889.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.04 to $272.01, inclusive."}],"balance_after":20758,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075651,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":2069,"price":270.56,"value":559788.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.04 to $271.01, inclusive."}],"balance_after":22842,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075650,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":1476,"price":269.61,"value":397944.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.01 to $269.95, inclusive."}],"balance_after":24911,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075649,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":1913,"price":268.5,"value":513640.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.00 to $268.82, inclusive."}],"balance_after":26387,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075648,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":1107,"price":267.47,"value":296089.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.98 to $267.85, inclusive."}],"balance_after":28300,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075647,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":593,"price":266.04,"value":157761.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.76 to $266.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":29407,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2075646,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-29T01:00:15.000Z","date":"2022-12-23","kind":"exercise","acquired":true,"shares":30000,"price":60.26,"value":1807800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000899243-22-039463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322039463/doc4.xml","form_type":"4"}},{"id":2375354,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-25T01:18:03.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":45000,"derivative":{"exercise_price":87.09,"expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-22-007775","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322007775/doc4.xml","form_type":"4"}},{"id":2839924,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":120646,"kind":"person","name":"Sukhija Remy","position":1,"cik":"0001806949","reported_name":"Sukhija Remy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-23T18:31:00.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":24000,"derivative":{"exercise_price":119.49,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000899243-21-007761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321007761/doc4.xml","form_type":"4"}}]}